MiniMed initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of MiniMed (MMED) with an Outperform rating and $20 price target Supported by a refreshed product pipeline with better form factor, outcomes, and patient experience, the firm expects MiniMed to sustain top line growth of nearly 10% and sees “an attractive buying opportunity in a turnaround story that has already begun to take hold under new management,” the analyst tells investors.